Last reviewed · How we verify
Aggressive lipid therapy
At a glance
| Generic name | Aggressive lipid therapy |
|---|---|
| Also known as | Rosuvastatin, Crestor |
| Sponsor | Annapoorna Kini |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease (PHASE2)
- Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion (PHASE3)
- Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome (PHASE3)
- Plaque Reversal With Early, Aggressive Lipid Lowering Therapy
- Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) (PHASE4)
- Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma (PHASE1, PHASE2)
- High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium (PHASE4)
- Management of Ventilation Acquired Pneumonia Caused by Pseudomonas and Acinetobacter Organisms in a Pediatric Center (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aggressive lipid therapy CI brief — competitive landscape report
- Aggressive lipid therapy updates RSS · CI watch RSS
- Annapoorna Kini portfolio CI